Singapore, July 3 -- STARMED, a South Korea-based medical device company specialising in minimally invasive treatment technologies, has announced that it has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for a thyroid-specific indication. The company's system may now be used for ultrasound-guided percutaneous ablation of eligible, cytologically confirmed benign thyroid nodules in adults.

The specificity of the labelling clearly distinguishes the clearance from a general soft-tissue ablation indication. The clearance directly names thyroid nodules, ultrasound guidance, the percutaneous approach, the adult patient population, and the applicable clinical eligibility criteria.

The cleared STAR RF Electrode is a ra...